Sibutramine is a weight-loss drug that was withdrawn from the market in 2010 due to its association with an increased risk of heart attack and stroke
Additionally, significantly lower levels of asparagine were also found, resulting from a probable deficiency of oxaloacetate and aspartate
Disclosures: Emmanuel Dixon: Nothing to Disclose, thierry claudel: Nothing to Disclose, Jakob-Wendelin Genger: Nothing to Disclose, Ci Zhu: Nothing to Disclose, Sarah Stadlmayr: Nothing to Disclose, Erika Paolini: Nothing to Disclose, Alexander Nardo: Nothing to Disclose, Veronika Mlitz: Nothing to Disclose, Claudia Fuchs: Nothing to Disclose, Andreas Bergthaler: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Wilfried Ellmeier: Nothing to Disclose, Michael Trauner: Albireo: Grant/Research Support, Alnylam: Grant/Research Support, Cymabay: Grant/Research Support, Falk: Grant/Research Support, Gilead: Grant/Research Support, Intercept: Grant/Research Support, MSD: Grant/Research Support, Takeda: Grant/Research Support, Ultragenyx: Grant/Research Support, Abbvie: Travel Grants, Falk: Travel Grants, Gilead: Travel Grants, Intercept: Travel Grants, Janssen: Travel Grants, Abbvie: Advisor, Albireo: Advisor, BiomX: Advisor, Boehringer Ingelheim: Advisor, Falk Pharma GmbH: Advisor, Genfit: Advisor, Gilead: Advisor, Hightide: Advisor, Intercept: Advisor, Ipsen: Advisor, Janssen: Advisor, MSD: Advisor, Novartis: Advisor, Phenex: Advisor, Pliant: Advisor, Regulus: Advisor, Siemens: Advisor, Shire: Advisor, BMS: Speaking and Teaching, Falk: Speaking and Teaching, Gilead: Speaking and Teaching, Intercept: Speaking and Teaching, Ipsen: Speaking and Teaching, Madrigal: Speaking and Teaching, MSD: Speaking and Teaching, Medical Universities of Graz and Vienna: Co.Inventor of patents for medical use of norUDCA filed by 2630 S-ADENOSYLMETHIONINE PROTECTS AGAINST FOLFOX-INDUCED LIVER INJURY BY INHIBITING PLASMINOGEN ACTIVATOR INHIBITOR-1 IN MICE Alexandra Gangi 1 Youngyi Lim 1 Tony Li 1 Andrea Floris 1 Swati Chandla 1 Maria Lauda Tomasi 1 Shelly Lu 1 , 1 Cedars Sinai Medical Center Background: Folinic acid, 5-Fluorouracil and Oxaliplatin (FOLFOX), a commonly used chemotherapeutic regimen in patients with colorectal liver metastasis (CRLM), can cause liver injury such as sinusoidal obstruction syndrome (SOS) that limits further treatment
Thanks to its melanin-inhibiting ingredients, this formula reduces the activity of tyrosinase the enzyme responsible for discoloration
Learn more about Melaleuca Alternifolia Leaf Extract Hydrolyzed Hyaluronic Acid is hyaluronic acid (HA) that is broken down into lower molecular weight fragments
Y., MILLS, R
